Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
FLORHAM PARK, N.J., Jan. 30, 2024 -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the...
Source: marketscreener.com